Tara Toth, PA
Medical · Baltimore, MDNPI 1700321171
Payments from drug & device makers
Across 55 payments — averaging $49.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$500
- Incyte Corporation$395
- Johnson & Johnson$346
- Sanofi-aventis U.S. LLC$232
- AstraZeneca$154
- Genmab U.S., Inc.$153
- plus $930 from 15 others
What the payments were for
- Speaking & faculty fees$50018%
- Food & beverage$2,04876%
- Education$1636%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 1 | $500 |
| Incyte Corporation | 9 | $395 |
| Johnson & Johnson | 9 | $346 |
| Sanofi-aventis U.S. LLC | 10 | $232 |
| AstraZeneca | 3 | $154 |
| Genmab U.S., Inc. | 2 | $153 |
| E.r. Squibb & Sons, L.L.C. | 1 | $127 |
| ADC Therapeutics America, Inc. | 1 | $125 |
| Biolinerx USA, Inc. | 1 | $110 |
| AbbVie | 3 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $96 |
| Gilead | 1 | $94 |
| Daiichi Sankyo Inc. | 3 | $88 |
| Syndax Pharmaceuticals, Inc. | 1 | $31 |
| Novartis | 2 | $30 |
| Amgen | 1 | $29 |
| Merck | 1 | $24 |
| Morphosys, US Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| BTG International Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,711 in reported general payments places this provider in the 75th percentile of 543 medical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 16 | $283,537 |
| JakafiRuxolitinib Phosphate | 12 | $198,477 |
| Posaconazole | 15 | $22,364 |
| Atovaquone | 42 | $19,205 |
| Entecavir | 13 | $10,604 |
| EliquisApixaban | 14 | $9,355 |
| ValacyclovirValacyclovir Hcl | 96 | $4,932 |
| Ursodiol | 16 | $1,356 |
| Pantoprazole Sodium | 15 | $385 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $374 |
| Acyclovir | 16 | $318 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 50 | $250 |
| Metoprolol Succinate | 11 | $198 |
| Famotidine | 12 | $157 |
| Penicillin V Potassium | 23 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCRezurock | $232 | $283,53716 claims |
| Incyte CorporationJakafi | $395 | $198,47712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 543 medical providers in Maryland.
Other medical in Baltimore
- Sarah SagorskyBaltimore$68K
- Maribeth HatalskiBaltimore$11K
- Edward MikulaBaltimore$11K
- Natalie OrbachBaltimore$10K
- Helen ReidlerBaltimore$10K
- Michelle DanielsBaltimore$9K
- Chana AbramsBaltimore$7K
- Joshua PertmanBaltimore$7K
- Victoria TrottStevensville$94K
- Emily GrisnikLeonardtown$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.